Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

8.9%

8 terminated/withdrawn out of 90 trials

Success Rate

87.9%

+1.4% vs industry average

Late-Stage Pipeline

40%

36 trials in Phase 3/4

Results Transparency

53%

31 of 58 completed trials have results

Key Signals

12 recruiting31 with results7 terminated

Enrollment Performance

Analytics

Phase 1

39(46.4%)

Phase 3

32(38.1%)

Phase 2

7(8.3%)

Phase 4

4(4.8%)

N/A

2(2.4%)

84Total

Phase 1(39)

Phase 3(32)

Phase 2(7)

Phase 4(4)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (90)

Showing 20 of 90 trials

NCT04627753Phase 2Recruiting

Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.

Role: collaborator

NCT06687928Phase 1Completed

To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab)

Role: lead

NCT06738719Phase 3Completed

A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis

Role: lead

NCT07533539Phase 1Recruiting

Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of L03TD1 in Healthy Volunteers

Role: lead

NCT07367958Phase 1Active Not Recruiting

A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P52 in Healthy Male Subjects

Role: lead

NCT05866614Active Not Recruiting

A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps

Role: lead

NCT07237516Recruiting

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

Role: collaborator

NCT06951828Phase 1Completed

A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P43 in Healthy Male Subjects

Role: lead

NCT06630559Phase 3Active Not Recruiting

A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis

Role: lead

NCT07200986Phase 1Active Not Recruiting

Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects

Role: lead

NCT07158346Phase 1Completed

Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in Healthy Volunteers

Role: lead

NCT06571591Phase 3Active Not Recruiting

Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin

Role: lead

NCT07128654Phase 1Completed

A Bioequivalence Study of CT-L02 Compared to Co-administration (CTL0201 and CTL0202) in Healthy Volunteers

Role: lead

NCT05385770Phase 3Completed

Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects

Role: lead

NCT06952478Phase 3Recruiting

A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma

Role: lead

NCT07013578Not ApplicableRecruiting

TIDHI Mental Health in IBD Patients Study

Role: collaborator

NCT07093476Phase 3Recruiting

Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

Role: lead

NCT04426890Phase 3Completed

To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria

Role: lead

NCT07054970Phase 1Completed

To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects